top of page

Daratumumab and atezolizumab to be evaluated in two studies

Janssen and Genentech are to initiate two studies to determine the safety and tolerability of daratumumab (Darzalex), the first CD38-directed monoclonal antibody (mAb), in combination with atezolizumab, an investigational mAb designed to bind with a protein called programmed cell death-ligand 1 (PD-L1).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page